(A) GLP-1(7-36) peptide comprising the sequence:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg (SEQ ID NO:2)

and

(B) a derivative of such peptide;

wherein the compound is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1(1-36) or GLP-1(1-37).

Please substitute the current version of the paragraph starting on page 5, line 22, and ending on page 6, line 9, with the following paragraph:

The invention also includes a compound selected from the group consisting of:

(A) GLP-1(7-36) peptide comprising the sequence:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg (SEQ ID NO:2)

D1

and

(B) a derivative of such peptide;

wherein the compound is substantially free of natural contaminants, and has an insulinotropic activity at a concentration of at least 10^{-10} M.

Please substitute the current version of the paragraph starting on page 6, line 10, and ending on page 7, line 2, with the following paragraph:

Of particular interest are GLP-1(7-36) peptides of the following formula:

(1) H_2N-X-CO-R^1

wherein R^1 is OH, OM, or $-NR^2R^3$;

M is a pharmaceutically acceptable cation or a lower branched or unbranched alkyl group;

R^2 and R^3 are the same or different and selected from the group consisting of hydrogen and a lower branched or unbranched alkyl group;

D2

X is a GLP-1(7-36) peptide comprising the sequence:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg (SEQ ID NO:2);

NH_2 is the amine group of the amino terminus of X; and

CO is the carbonyl group of the carboxy terminus of X and where the naturally processed form is arginineamide at position 36 of GLP-1(7-36);

(2) the acid addition salts thereof; and

(3) the protected or partially protected derivatives thereof;

wherein such compound has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1(1-36) or GLP-1(1-37).

D2 Cont

Please substitute the current version of the paragraph starting on page 7, line 12, and ending on page 7, line 14, with the following paragraph:

Figure 1 shows the DNA structure (SEQ ID NO:1) and corresponding amino acid sequence (SEQ ID NO:2) of rat preproglucagon. The preproglucagon precursor is proteolytically cleaved at sites indicated by circles.

D3